作者: Qingxin Liu , Yun Zhang , Danielle Jernigan , Alessandro Fatatis
DOI: 10.1007/978-94-007-2558-4_11
关键词: Complication 、 Zoledronic acid 、 Standard of care 、 Prostate cancer 、 Secondary tumors 、 Internal medicine 、 Adrenergic receptor 、 Disease 、 Oncology 、 Medicine 、 Platelet-derived growth factor
摘要: Skeletal dissemination is by far the most feared complication of prostate cancer and main cause patients’ demise. Today, 85% patients are diagnosed with in absence clinically evident secondary tumors. However, a significant number these will eventually develop advanced form disease present skeletal metastases. A definitive, curative treatment for bone metastatic still an unmet clinical need current standard care relies on merely palliative measures.